ESNC yields 2000000.00% · ABBV yields 3.06%● Live data
📍 ESNC pulled ahead of the other in Year 1
Combined, ESNC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESNC + ABBV for your $10,000?
EnSync, Inc., together with its subsidiaries, develops, licenses, and manufactures energy management systems solutions for the residential and commercial energy systems, and independent utility energy systems markets in the United States and internationally. The company's products include Matrix energy management, an energy control system for the commercial and residential energy systems markets; Home Energy System for property developers and residential customers; and DER SuperModule system, a self-contained DER system that integrates with renewable generation, customer load, and grid interconnection for deploying the least expensive, highest value, and most reliable electricity. Its products also comprise DER Flex Internet of energy control platform, a software platform that seamlessly connects to DERs; True Peer-to-PeerTM energy exchange technology; and Hybrid energy storage system. The company was formerly known as ZBB Energy Corporation and changed its name to EnSync, Inc. in August 2015. EnSync, Inc. was founded in 1986 and is headquartered in Menomonee Falls, Wisconsin.
Full ESNC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.